Submission of the 38th Annual Report of Fredun Pharmaceuticals Limited for the Financial Year 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has filed its 38th Annual Report for FY 2024-25 with BSE, along with the notice for its 38th Annual General Meeting scheduled for September 30, 2025 at 9:00 AM via video conferencing. Key items up for shareholder approval include a 7% dividend on equity shares, re-appointment of Managing Director Fredun Nariman Medhora (who retires by rotation), appointment of two new Independent Directors (Mr. Anshu Agarwal and Ms. Sonal Dharmin Desai) for five-year terms, ratification of Cost Auditor remuneration of Rs. 1.25 lakh, and approval for related party transactions up to Rs. 1 crore per transaction for FY 2025-26. The Managing Director's message highlights expansion into pet and veterinary care (including the launch of FREOSSI Large Animals, Fredna Vet Diagnostics centre, and acquisition of One Pet Stop Pvt Ltd), entry into functional foods, and a longer-term plan to build a branded generics business under 'Fredun Gx'. The company also noted the sad demise of Non-Executive Director Mr. Nariman Medhora on June 20, 2025, and a change in Company Secretary during the year.
Shareholders can expect a 7% dividend if approved at the AGM on September 30. The filing is a routine regulatory submission under SEBI's Listing Regulations and includes standard governance items, with no immediate negative implications for the stock.